

## SeromYx Systems Announces Strategic Collaboration to Advance Understanding and Treatment of Long COVID

**Woburn, MA, September, 25<sup>th</sup>, 2024** – [SeromYx Systems](#), a leading provider of GCLP Systems Serology and Antibody characterization services, is excited to announce a new immunobiology collaboration to better understand Post-Acute Sequelae of SARS-CoV-2 infection (PASC), otherwise known as Long COVID.

The work is being done in collaboration with renowned HHMI investigator and Sterling Professor of Immunobiology and Molecular, Cellular, and Developmental Biology at Yale School of Medicine, Dr. Akiko Iwasaki, and her team at [Yale's Center of Infection & Immunity](#).

Long COVID presents a myriad of symptoms and conditions that persist in patients for extended periods following the initial SARS-CoV-2 infection. Recognizing the significance of this issue, SeromYx will be spearheading a groundbreaking initiative to conduct comprehensive biophysical and cellular Fc-effector function profiling of serum samples obtained from long COVID patients within specific cohorts of the Mount Sinai-Yale Long COVID (MY-LC) Study. Dr. David Putrino led patient recruitment efforts at Mount Sinai in collaboration with Iwasaki and her team at Yale. Putrino is the Director of Rehabilitation Innovation for the Mount Sinai Health System, and he is the Nash Family Director of the Cohen Center for Recovery from Complex Chronic Illnesses (CoRE). The MY-LC cohort is one of the most comprehensively characterized Long COVID human cohorts, where in addition to health data, extensive multi-omics datasets are available. These include deep immune profiling, plasma proteomics, autoantibody profiling, serum epitope repertoire analyses, and more, as recently described (Klein *et al*, Nature 2023). The new comprehensive study planned by the Yale-SeromYx collaboration is poised to yield new key molecular insights, which leveraging the existing rich datasets, promise to illuminate the mechanisms driving this complex disease.

This collaboration signifies an important step towards gaining valuable immunologic insights that may substantially enhance the diagnosis and treatment of Long COVID. By combining SeromYx's expertise in Systems Serology with Yale's innovative multi-dimensional approaches to biological analysis, we aim to contribute significantly to the understanding and management of this complex condition.

"We are thrilled to work with Dr. Akiko Iwasaki and her exceptional team at Yale School of Medicine in this important endeavor," said Lenny Moise, VP, Research at SeromYx Systems. "Together, we are committed to driving advancements in the field of immunology and making meaningful strides in addressing the challenges posed by Long COVID."

This collaboration underscores SeromYx Systems' dedication to leveraging cutting-edge technologies and strategic partnerships to tackle pressing healthcare issues. The company looks forward to a fruitful collaboration with Iwasaki's Lab and anticipates the

positive impact that this joint effort will have on the lives of individuals affected by Long COVID.

For more information about SeromYx Systems and its pioneering work in Systems Serology services, visit <https://www.seromyx.com/>.

**About SeromYx Systems:**

SeromYx Systems is a global leader in providing GCLP high-throughput antibody characterization services and Systems Serology, offering advanced solutions for the comprehensive analysis of immune responses. With a dedication to innovation and excellence, SeromYx is at the forefront of revolutionizing the field of immunology through its cutting-edge technologies and strategic collaborations.

**Contact:**

Abigail Harris

Business Development Manager

[Abigail.Harris@seromyx.com](mailto:Abigail.Harris@seromyx.com)

